DiaMedica Therapeutics (DMAC) Cash from Operations (2018 - 2026)
DiaMedica Therapeutics (DMAC) posted quarterly Cash from Operations of 9082000.0 for Q1 2026, down 27.04% year-over-year from 12447702.84 in Q1 2025, and down 17.01% quarter-over-quarter from 7762000.0 in Q4 2025.
DiaMedica Therapeutics (DMAC) Cash from Operations (2018 - 2026) Analysis & Trends
DiaMedica Therapeutics' Cash from Operations history runs 9 years deep, the most recent figure standing at 9082000.0 for Q1 2026.
- In Q1 2026, Cash from Operations fell 27.04% year-over-year to 9082000.0; the TTM figure through Mar 2026 stood at 30995000.0 (down 37.32% YoY), while the FY2025 annual figure was 29062000.0, down 31.65% from the prior year.
- Cash from Operations for Q1 2026 stood at 9082000.0, down from 7762000.0 in the prior quarter.
- The five-year high for Cash from Operations was 2361000.0 in Q3 2022, with the low at 9082000.0 in Q1 2026.
- The 5-year median for Cash from Operations is 5030000.0 (2023), against an average of 5321117.65.
- The sharpest annual moves came in 2022 and 2023: Cash from Operations advanced 22.49% in 2022, then plunged 103.18% in 2023.
- DiaMedica Therapeutics' Cash from Operations stood at 2766000.0 in 2022, then slumped by 37.82% to 3812000.0 in 2023, then slumped by 68.78% to 6434000.0 in 2024, then fell by 20.64% to 7762000.0 in 2025, then declined by 17.01% to 9082000.0 in 2026.
- Business Quant data shows DMAC's Cash from Operations at 9082000.0 in Q1 2026, 7762000.0 in Q4 2025, and 6553000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -387.32 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 462.82 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -1.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 728.46 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 326.72 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -88.83 Mn |
| 10 | DiaMedica Therapeutics | 360.22 Mn | 360.22 Mn | - | -8.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -8.10 Mn |
| Jun 30, 2026 | -8.10 Mn |
| Mar 31, 2026 | -9.08 Mn |
| Mar 31, 2026 | -9.08 Mn |
| Dec 31, 2025 | -7.76 Mn |
| Dec 31, 2025 | -7.76 Mn |
| Sep 30, 2025 | -6.55 Mn |
| Sep 30, 2025 | -6.55 Mn |
| Jun 30, 2025 | -7.60 Mn |
| Jun 30, 2025 | -7.60 Mn |
| Mar 31, 2025 | -7.15 Mn |
| Mar 31, 2025 | -7.15 Mn |
| Dec 31, 2024 | -6.43 Mn |
| Dec 31, 2024 | -6.43 Mn |
| Sep 30, 2024 | -4.47 Mn |
| Sep 30, 2024 | -4.47 Mn |
| Jun 30, 2024 | -4.52 Mn |
| Jun 30, 2024 | -4.52 Mn |
| Mar 31, 2024 | -6.65 Mn |
| Mar 31, 2024 | -6.65 Mn |